Vivos Therapeutics Inc Cash Flow Conversion Efficiency
Vivos Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has a cash flow conversion efficiency ratio of 0.790x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.15 Million) by net assets ($-3.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vivos Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2025. This chart illustrates how Vivos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VVOS stock price for real-time trading data and today's change.
Vivos Therapeutics Inc Cash Flow Conversion Ratio Explained
Vivos Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vivos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivos Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Vivos Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Young & Co.'s Brewery P.L.C
LSE:YNGN
|
0.046x |
|
Merko Gida Sanayi ve Ticaret AS
IS:MERKO
|
-0.019x |
|
Realites
PA:ALREA
|
-0.231x |
|
L Agence Automobiliere SA
PA:MLAA
|
N/A |
|
Uscom Ltd
AU:UCM
|
-7.065x |
|
Silly Monks Entertainment Limited
NSE:SILLYMONKS
|
0.065x |
|
Grand Gulf Energy Ltd
AU:GGE
|
-0.003x |
|
Parabellum Resources Ltd
AU:PBL
|
-0.101x |
Annual Cash Flow Conversion Efficiency for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2025. Review how financially flexible is Vivos Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.55 Million | $-15.26 Million | 9.847x | +717.16% |
| 2024-12-31 | $7.95 Million | $-12.69 Million | -1.596x | +94.51% |
| 2023-12-31 | $411.00K | $-11.95 Million | -29.066x | -612.43% |
| 2022-12-31 | $4.80 Million | $-19.59 Million | -4.080x | -562.18% |
| 2021-12-31 | $25.54 Million | $-15.73 Million | -0.616x | -83.50% |
| 2020-12-31 | $16.92 Million | $-5.68 Million | -0.336x | -118.50% |
| 2019-12-31 | $-2.94 Million | $-5.34 Million | 1.815x | +264.83% |
| 2018-12-31 | $4.83 Million | $-5.31 Million | -1.101x | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more